## Edgar Filing: CORE LABORATORIES N V - Form 4

CORE LABORATORIES N V         Form 4         January 04, 2017         FORM 4         Magnetic dependence         VINTED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549         Check this box if no longer subject to Section 16. Form 4 or Form 5 on obligations may continue.       MB STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1935, of the Investment Company Act of 1935 or Section 1(b).       State							
(Print or Type Responses)							
BERGMARK RICHARD L Symbol		er Name <b>and</b> Ticker of LABORATORIE	-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (M 6316 WINDFERN ROAD		of Earliest Transaction Day/Year) 2016		X Director X Officer (give below) E		Owner r (specify	
(Street)	endment, Date Origina onth/Day/Year)	al	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
HOUSTON, TX 77040				Person		portung	
(City) (State)	(Zip) Tab	ole I - Non-Derivative	Securities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction(A) or D Code (Instr. 3,	-	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common 12/30/2016 Shares		M 8,001	A \$0	64,078	D		
Common 12/30/2016 Shares		F 2,777	D \$ 120.04	61,301	D		
Common Shares				69,802	Ι	401(k) Plan	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: CORE LABORATORIES N V - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8 C S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Performance Shares	\$ 0	12/30/2016		М	8,001	<u>(1)</u>	<u>(1)</u>	Common Shares	8,001	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b>x</b> 0	Director	10% Owner	Officer	Other	
BERGMARK RICHARD L 6316 WINDFERN ROAD HOUSTON, TX 77040	Х		EVP & CFO		
Signatures					
/s/ Mark Elvig, Attorney-in-Fact	01	/04/2017			

Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares vesting were awarded as restricted performance shares in February 2014. As reported in the Form 4 filing on February 10, 2014 at the time the award was made, "The restricted performance shares will vest only upon the Company's return on invested capital

(1) being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period and the shares shall fully vest if that criterion is met. If it is not met, then no shares shall vest and the award shall be forfeited." The performance criteria and all requirements for vesting have been met and thus the shares fully vested on December 30, 2016, at the conclusion of the performance period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.